Validation of circulating tumor cells (CTC) detection techniques in patients with advanced solid tumors

Validation of circulating tumor cells (CTC) detection techniques in patients with advanced solid tumors - CTC detection in advanced solid tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33920

Enrollment

200

Registered

2008-08-07

Start date

2008-06-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who are treated for advanced solid tumors; Age of 18 years or older; Able and willing to give written informed consent; Able and willing to undergo veni-puncture; Life expectancy of 3 months or more; WHO performance status of 0, 1 or 2;

Exclusion criteria

Exclusion criteria: Any condition that may interfere with the study protocol

Design outcomes

Primary

Measure	Time frame
Primary objective To optimize CTC detection assay sensitivity and specificity in different types of advanced solid tumors by comparison of enrichment techniques and expression level of a panel of selected marker genes. Amendment: To compare CTC detection results of the FAST cytometry method to the qRT-PCR method.	—

Secondary

Measure	Time frame
Secondary objectives To determine intra-patient variation of CTC detection assay outcome. To assess inter-patient variation in CTC detection assay outcome. To determine which CTC detection assay is best suitable in the population of patients that participate in clinical trials.	—

Countries

Netherlands

Outcome results